Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity’s SEC disclosures run hundreds of pages, weaving together diagnostics, genomic screening, and mass-spectrometry businesses that follow very different regulations. Finding where the 10-K hides newborn-screening revenue or which subsidiaries fuel instrument sales can slow even seasoned analysts. That’s why Stock Titan’s platform steps in—AI-powered summaries translate every footnote, ratio, and risk factor into plain language, giving you Revvity SEC filings explained simply.
Need the latest Revvity quarterly earnings report 10-Q filing or to monitor Revvity insider trading Form 4 transactions? Our real-time feed surfaces each document the moment it hits EDGAR and attaches concise highlights: segment revenue trends, R&D spend on high-throughput assays, and liquidity updates tied to recent acquisitions. Interactive dashboards let you dive into Revvity 8-K material events explained, receive instant push alerts on Revvity Form 4 insider transactions real-time, and compare pay packages straight from the Revvity proxy statement executive compensation table.
Whether you’re stress-testing cash flow models, tracking supply-chain disclosures, or scanning Revvity annual report 10-K simplified for warranty liabilities, Stock Titan converts dense text into actionable insight. Practical use cases include: spotting instrument backlog swings before earnings, flagging Revvity executive stock transactions Form 4 ahead of clinical-trial milestones, and running side-by-side Revvity earnings report filing analysis across quarters. In short, understanding Revvity SEC documents with AI means less time searching and more time making informed decisions.
Revvity, Inc. (RVTY) reported Q3 results with total revenue of $698.9 million, up 2% year over year. Diluted EPS was $0.40 as net income declined to $46.7 million amid higher interest and other expenses. Gross margin fell 266 bps to 53.6% and operating margin also compressed, driven by increased tariffs, unfavorable foreign exchange, and product mix.
By segment, Diagnostics rose 3% to $356.1 million, led by Reproductive Health, while Life Sciences inched up 1% to $342.8 million on stronger Software. Year‑to‑date cash from operations was $407.0 million. The company repurchased 6.75 million shares for $647.9 million year to date, ending the quarter with 114.0 million shares outstanding, and the Board authorized a new $1.0 billion repurchase program on October 23, 2025. The quarterly dividend remained $0.07 per share.
Revvity, Inc. (RVTY) President, Chief Executive Officer and Director Prahlad R. Singh reported a bona fide gift of 9,420 shares of common stock on 10/29/2025.
The shares were transferred to an irrevocable trust for the sole benefit of his children, with his spouse serving as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Following the transaction as of October 29, 2025, Singh beneficially owned 96,838 shares direct and 46,583 shares indirect through the Singh Family Trust of 2021.
Revvity (RVTY) appointed Anita Gonzales as Vice President and Chief Accounting Officer, effective October 23, 2025. Gonzales has served as the company’s Vice President and Controller since May 2023, after joining in March 2021 to lead integration and controllership initiatives. She previously spent a decade at General Electric in corporate audit and GE Aviation leadership roles, and earlier advanced to Senior Manager at PwC. Gonzales holds MPA and BBA degrees from the University of Texas at Austin and is a CPA.
Maxwell Krakowiak, Senior Vice President and Chief Financial Officer of Revvity, Inc. (RVTY), reported a transaction dated 09/15/2025 in which he surrendered 559 shares of Revvity common stock at an effective price of $82.87 per share. The filing shows 12,217 shares beneficially owned following the transaction, held directly. The Form 4 explains these shares were surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on 09/15/2022. The form was signed by a power of attorney on behalf of the reporting person on 09/17/2025.
Anita Gonzales, Vice President and Controller of Revvity, Inc. (RVTY), reported the surrender of 149 shares of common stock on 09/15/2025 at a price of $82.87 per share to satisfy tax withholding obligations arising from restricted stock units originally granted on 09/15/2022. After this transaction, the reporting person beneficially owned 4,340 shares, held directly. The Form 4 filing was submitted by power of attorney on 09/17/2025.
This disclosure reflects a routine, non-cash settlement of vested equity for tax purposes rather than an open-market sale or purchase. The filing identifies the transaction code and ties the share reduction explicitly to the RSU agreement, indicating compliance with Section 16 reporting requirements.
Alexis P. Michas, a director of Revvity, Inc. (RVTY), reported a sale of common stock on 08/27/2025. The filing shows 500 shares were disposed of at a price of $89.01. The report records 7,270 shares as beneficially owned indirectly through The Cayre and Alexis Michas Foundation Corp., and the filing includes an explanation that certain reported shares relate to dividends in the Reporting Person's Deferred Compensation Plan account. The filing is signed by a power of attorney on behalf of the reporting person and includes the foundation disclosure that the Reporting Person disclaims beneficial ownership of foundation-held shares except to the extent of any pecuniary interest.
Revvity, Inc. (RVTY) Form 144 notifies the proposed sale of 500 shares of common stock through Merrill Lynch with an aggregate market value of $44,000.00. The filing lists total shares outstanding as 116,072,580 and an approximate sale date of 08/27/2025. The securities were acquired on 04/26/2005 as a stock bonus from Revvity and payment is recorded as stock bonus. The filer reports nothing to report for securities sold in the past three months. The form includes the standard representation that the seller is not aware of undisclosed material adverse information.
Tajinder S. Vohra, Senior Vice President, Global Operations of Revvity, Inc. (RVTY), reported a transfer of 12,183 shares of Revvity common stock on 08/15/2025. The filing shows a Disposition (code G) of 12,183 shares at $0 and a concurrent Acquisition (code G) of 12,183 shares by the reporting person’s revocable family trust.
The report lists 10,442 shares still held directly by Vohra after the transfer and 12,183 shares held indirectly by the Vohra Family Trust. The explanatory note states the transfer was to a revocable trust of which the reporting person and spouse are joint trustees, that there was no purchase or sale, and that the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Revvy, Inc. insider filing (Form 4) reports a stock option grant to Victor Miriame, Senior Vice President and Chief Commercial Officer. The filing shows a non-qualified stock option to purchase 32,382 shares of Revvity common stock at an exercise price of $90.465 per share. The transaction date is 08/15/2025 and ownership is direct. The option has a seven-year term and is scheduled to fully vest on the third anniversary of the grant, indicating vesting completes three years after the grant date. The form was signed by a power of attorney on behalf of the reporting person.
FAQ
What is the current stock price of Revvity (RVTY)?
What is the market cap of Revvity (RVTY)?
